Sanofi-Synthelabo S.A sales and marketing update

SNY launched in the U.S. its Eloxatin oxaliplatin chemotherapeutic to treat metastatic colorectal cancer in combination with 5-FU and leucovorin. Eloxatin, which already is marketed in more than 55 o...